Merck Enters Non-Binding MoU with Afrigen Biologics to Develop mRNA Vaccine Technology Platform
Merck, a prominent science and technology company, has announced a non-binding Memorandum of Understanding (MoU) through its Life Science business sector with Afrigen Biologics to bolster the development of an mRNA vaccine technology platform. This collaboration aims to advance mRNA…